Precision oncology matches each patient with the therapy most likely to work, based on the molecular profile of their tumor. For molecular labs, that means turning somatic NGS data into reliable, actionable results: detecting SNVs, indels and CNVs, and assessing genomic signatures such as HRD, MSI and TMB that guide treatment decisions.
In this section, we share our latest articles on precision oncology: case studies from labs using SeqOne for somatic analysis, scientific insights on biomarkers like homologous recombination deficiency, and updates on how our platform helps teams deliver faster, clinically validated cancer reports.

Meet UP²-SV: a dedicated AI pathogenicity classifier for structural variants, trained on 65,000+ ClinVar SVs and validated on a clinical cohort with 97.6% sensitivity. AI-powered prioritization now spans the full variant spectrum.
A Spanish hospital ended a patient's 30-year diagnostic odyssey by combining Agilent's advanced exome sequencing with SeqOne's AI platform, uncovering a rare DMD gene duplication that had eluded detection for decades.

Genekor Medical, a Romanian diagnostics lab, uses SeqOne's platform to make HRD testing a routine clinical workflow. Using shallow whole genome sequencing and automated FASTQ-to-GIS analysis, they've cut complexity and costs, proving that reliable precision oncology testing is achievable for regional labs beyond major European hubs.